Angiotensin-converting enzyme-2 (ACE-2) is an essential element in the renin-angiotensin RAS system and plays a key role in coronavirus entrance to the human body and attachment to the cell. Variation in ACE-2 may increase the capability of coronavirus to binding with human tissues and lead to variation in disease severity among patients. For this reason, this study aimed to take some SNPs in different COVID-19 patient cases to show the possible role of Angiotensin-Converting Enzyme-2 (ACE2) polymorphism in people that could have severe infections caused by SARS-CoV-2 by detecting different single nucleotide polymorphisms SNPs on this gene by PCR-sequencing. This cross-sectional study includes 100 diagnosed COVID-19 patients during a period between November and December 2021. The result revealed that three SNPs rs1463669655, rs746202722, and rs201035388 located on ACE-2 (GRCh38.p13) gene did not associate with the severity of COVID-19 disease because all patients have either the wildtype or the heteterotype allele as the following 0 % GG, 100 % AG, and 0% AA as the genotype distribution in severe cases, and the genotype distribution in non-severe cases was 0 % GG, 100 %AG, and 0 % AA and 100 % AA, 0 % AG, and 0% GG as the genotype distribution in severe cases, and the genotype distribution in non-severe cases was 100 % AA, 0 %AG, and 0 % GG and 100 % GG, 0 % GA, and 0% AA as the genotype distribution in severe cases, and the genotype distribution in non-severe cases was 100 % GG, 0 %GA, and 0 % AA for these three SNPs respectively. The ACE-2 angiotensin-converting enzyme gene was studied because of its active participation in the entry of the Coronavirus into the human body and its binding to alveolar cells and concluded that three SNPs rs1463669655, rs746202722, and rs201035388 located on ACE-2(GRCh38.p13) gene did not associate with the severity of COVID-19 disease.
Angiotensin-converting enzyme-2 (ACE-2) gene polymorphism, COVID-19 polymerase chain reaction (PCR), Single nucleotide polymorphisms (SNPs)
Cao, Y., Li, L., Feng, Z., Wan, S., Huang, P., Sun, X., Wen, F., Huang, X., Ning, G. & Wang, W. (2020). Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery, 6, 11. https://doi.org/10.1038/s41421-020-0147-1
Chen, F., Zhang, Y., Li, X., Li, W., Liu, X. & Xue, X. (2021). The impact of ACE2 polymorphisms on COVID-19 disease: Susceptibility, severity, and therapy. Frontiers in Cellular and Infection Microbiology, 11, 753721. https://doi.org/10.3389/fcimb.2021.753721
Devaux, C. A., Rolain, J. M., & Raoult, D. (2020a). ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology, and Infection, 53(3), 425–435. https://doi.org/10.1016/j.jmii.2020.0 b4.015
Devika, S. (2021). On the origin and evolution of SARS-CoV-2. Experimental and Molecular Medicine, 53, 1–7
Green, M. R. & Sambrook, J. (2012). Molecular cloning. A Laboratory Manual 4th.
Harrison, S. C. (2015). Viral membrane fusion. Virology, 479–480, 498–507. https://doi.org/10.1016/j.virol.2015.03.043
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C. & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Lee, S. H., Yang, J., Goddard, M. E., Visscher, P. M., & Wray, N. R. (2012). Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. Bioinformatics, 28(19), 2540–2542. https://doi.org/10.1093/bioinformatics/bts474
Lopera Maya, E. A., van der Graaf, A., Lanting, P., van der Geest, M., Fu, J., Swertz, M., Franke, L., Wijmenga, C., Deelen, P., Zhernakova, A., Sanna, S. & Lifelines Cohort Study. (2020). Lack of association between genetic variants at ACE2 and TMPRSS2 genes involved in SARS-CoV-2 infection and human quantitative phenotypes. Frontiers in Genetics, 11, 613. https://doi.org/10.3389/fgene.2020.00613
Möhlendick, B., Schönfelder, K., Breuckmann, K., Elsner, C., Babel, N., Balfanz, P., Dahl, E., Dreher, M., Fistera, D., Herbstreit, F., Hölzer, B., Koch, M., Kohnle, M., Marx, N., Risse, J., Schmidt, K., Skrzypczyk, S., Sutharsan, S., Taube, C., . . . & Kribben, A. (2021). ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenetics and Genomics, 31(8), 165–171. https://doi.org/10.1097/FPC.0000000000000436
Suryamohan, K., Diwanji, D., Stawiski, E. W., Gupta, R., Miersch, S., Liu, J., Chen, C., Jiang, Y. P., Fellouse, F. A., Sathirapongsasuti, J. F., Albers, P. K., Deepak, T., Saberianfar, R., Ratan, A., Washburn, G., Mis, M., Santhosh, D., Somasekar, S., Hiranjith, G. H., . . . & Seshagiri, S. (2021). Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Communications Biology, 4(1), 475. https://doi.org/10.1038/s42003-021-02030-3
Wang, L., Zhao, L., Li, Y., Ma, P., Kornberg, R. D. & Nie, Y. (2022). Harnessing coronavirus spike proteins’ binding affinity to ACE2 receptor through a novel baculovirus surface display system. Biochemical and Biophysical Research Communications, 606, 23–28. https://doi.org/10.10 16/j.bbrc.2022.03.062
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) © Author (s)